ArticleEuropean journal of nuclear medicine and molecular imaging2026
PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CT.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- On the conceptual framing of whole-body metabolic burden in multiple myeloma.Annals of nuclear medicine · 2026Article
- Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: AnMolecular imaging and radionuclide therapy · 2026Article
- Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMultiple myeloma (MM) frequently evades complete evaluation with 18 F-FDG-PET/CT due to variable hexokinase expression, leading to false-negative findings. 18 F-fluorocholine-PET/CT (FCH) targets membrane phospholipid synthesis and has been proposed as an alternative imaging strategy to address this limitation.
methodsIn this single-center retrospective study, 35 adult MM patients underwent dual-tracer PET/CT within four weeks. Lesions were scored using Deauville-based criteria (IMPeTUs), and exploratory composite scores (hTepe and myPET) were calculated. Laboratory markers, including M-protein, free light chains, and bone marrow infiltration, were collected within four weeks of imaging.
resultsThe cohort (22 men, 13 women; mean age 62.2 ± 10.9 years) included 19 patients at initial staging and 16 at restaging. FDG detected active disease in 49% of patients, with 50.0% sensitivity and 100% positive predictive value (PPV). FCH identified disease in 91%, achieving 94.1% sensitivity and 100% PPV. Median bone marrow Deauville scores were similar (score-3), but FCH demonstrated significantly higher hypermetabolic focus scores (median 4 vs. 1; p < 0.001). FCH uptake moderately correlated with marrow plasma cell infiltration and inversely with hemoglobin and albumin, whereas FDG showed no consistent biochemical associations.
conclusionFCH demonstrates superior diagnostic performance compared to FDG in MM, particularly in red marrow-rich regions. FCH more reliably reflects disease burden and aligns more closely with laboratory markers, supporting its role in staging, residual disease assessment, and treatment monitoring. Collectively, these results highlight FCH as a clinically applicable biomarker of disease burden with potential utility in routine staging and response evaluation in multiple myeloma.
Indexed as
Identifiers
41128865What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.